Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

被引：9
|
作者：
Pratz, Keith W.
DiNardo, Courtney D.
Selleslag, Dominik
Li, Junmin
Yamamoto, Kazuhito
Konopleva, Marina
McDonald, Andrew
Babu, Sunil
Stevens, Don A.
Kantarjian, Hagop M.
Traina, Fabiola
Venditti, Adriano
Mayer, Jiri
Montez, Melissa
Ramsingh, Giridharan
Jin, Huan
Ainsworth, William
Duan, Yinghui
Svensson, Anders Erik
Werner, Michael
Potluri, Jalaja
Jonas, Brian A.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134832
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Venetoclax and Posaconazole Plus Standard Dose Cytarabine or Azacytidine for Newly Diagnosed Acute Myeloid Leukemia
    Tran-Der Tan
    Chiou, Lun-Wei
    BLOOD, 2020, 136
  • [32] Unmodified Dose of Azacitidine Plus Venetoclax Regimen without Drug Interactions during the First Cycle Leads to Similar Outcomes between Viale-a Clinical Trial and Real-Life in Acute Myeloid Leukemia
    Sedaki, Bochra
    Iat, Alexandre
    Loschi, Michael
    Benachour, Sami
    Chiche, Edmond
    Ryffel, Lea
    Brugel, Patricia
    Sudaka, Isabelle
    Aquaronne, Daniele
    Ferrero, Corinne
    Dadone, Berengere
    Cluzeau, Thomas
    BLOOD, 2022, 140 : 11718 - 11719
  • [33] Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
    Kadia, Tapan M.
    Reville, Patrick K.
    Wang, Xuemei
    Rausch, Caitlin R.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval G. G.
    DiNardo, Courtney D. D.
    Sasaki, Koji
    Issa, Ghayas C. C.
    Ohanian, Maro
    Montalban-Bravo, Guillermo
    Short, Nicholas J. J.
    Jain, Nitin
    Ferrajoli, Alessandra
    Bhalla, Kapil N. N.
    Jabbour, Elias
    Takahashi, Koichi
    Malla, Rashmi
    Quagliato, Kelly
    Kanagal-Shamanna, Rashmi
    Popat, Uday R. R.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina Y. Y.
    Ravandi, Farhad
    Kantarjian, Hagop M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3848 - +
  • [34] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
  • [35] Molecular Measurable Residual Disease in Patients with Newly Diagnosed m IDH1 Acute Myeloid Leukemia Treated with Ivosidenib plus Azacitidine
    DiNardo, Courtney D.
    Marchione, Dylan
    Heuser, Michael
    Hui, Jianan
    Gianolio, Diego
    Daigle, Scott
    Choe, Sung
    Patel, Prapti
    De Botton, Stephane
    Dohner, Hartmut
    BLOOD, 2023, 142
  • [36] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Maximilian Fleischmann
    Sebastian Scholl
    Jochen J. Frietsch
    Inken Hilgendorf
    Karin Schrenk
    Jakob Hammersen
    Florian Prims
    Christian Thiede
    Andreas Hochhaus
    Ulf Schnetzke
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3191 - 3202
  • [37] Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
    Jonas, Brian A.
    Wei, Andrew H.
    Recher, Christian
    DiNardo, Courtney D.
    Jang, Jun-Ho
    Pratz, Keith
    Panayiotidis, Panayiotis
    Montesinos, Pau
    Yeh, Su-Peng
    Ivanov, Vladimir
    Fiedler, Walter
    Yamauchi, Takahiro
    Duan, Yinghui
    Mendes, Wellington
    Potluri, Jalaja
    Tews, Bjorn
    Ofran, Yishai
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : E299 - E303
  • [38] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Fleischmann, Maximilian
    Scholl, Sebastian
    Frietsch, Jochen J.
    Hilgendorf, Inken
    Schrenk, Karin
    Hammersen, Jakob
    Prims, Florian
    Thiede, Christian
    Hochhaus, Andreas
    Schnetzke, Ulf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3191 - 3202
  • [39] Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
    Cui, Jingying
    Chen, Xuexing
    Li, Chunfang
    Yan, Qiong
    Yuan, Guolin
    HEMATOLOGY, 2024, 29 (01)
  • [40] Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective
    Pratz, Keith W.
    Chai, Xinglei
    Xie, Jipan
    Yin, Lei
    Nie, Xiaoyu
    Montez, Melissa
    Iantuono, Erica
    Downs, Lisa
    Ma, Esprit
    BLOOD, 2021, 138
12345